Get the Daily Brief
Latest Biotech News
New Soil Metagenomic Techniques Uncover Novel Antibiotics
Researchers at Rockefeller University have developed a groundbreaking long-read sequencing technique that bypasses traditional culturing methods to explore the vast diversity of soil microbiomes....
Positive Phase II Alzheimer’s Data from Remynd NV’s Neuronal Calcium Modulator
Remynd NV reported encouraging Phase IIa clinical trial results for its novel Alzheimer's drug candidate REM-127. The orally administered small molecule restores calcium homeostasis in neurons,...
Capsida Biotherapeutics Pauses Gene Therapy Trial After First Patient Death
Capsida Biotherapeutics has suspended its phase I/II Synrgy trial testing CAP-002, a gene therapy for pediatric STXBP1 encephalopathy, following the death of the first enrolled patient. The trial...
Biopharma Capital Markets: LB Pharma IPO and Avidity Biosciences Raise Provide Momentum
LB Pharmaceuticals completed a successful NASDAQ IPO, raising $285 million to fund clinical trials for its schizophrenia and bipolar depression drug LB-102. Investor enthusiasm prompted an upsized...
Sapio Sciences and Ultima Genomics Forge Multi-Omics Technology Partnership
Sapio Sciences and Ultima Genomics announced a strategic partnership to integrate Sapio's AI-driven laboratory informatics platform with Ultima's high-throughput, low-cost sequencing technology....
FDA and Biopharma Leadership Changes Shake Industry Landscape
Vinay Prasad reclaimed chief medical and scientific officer roles at the FDA’s Center for Biologics Evaluation and Research following his recent return. Eli Lilly appointed a former FDA cell and...
Biosimilars Face Adoption Hurdles Despite Cost Savings in U.S. Market
A detailed July 2025 report highlights that FDA-approved biosimilars have generated $56.2 billion in savings since 2015 but face uneven market adoption across therapeutic areas. Despite potential...
Merck and AstraZeneca Curtail UK R&D Investments Amid Policy Uncertainty
Merck's decision to exit its London R&D hub intensifies concerns about the UK's life sciences policies, underscoring challenges the sector faces amid a competitive global landscape. AstraZeneca...
AI Advances in Peptide Therapeutics Transform Drug Discovery
AI-driven peptide design is revolutionizing the development of novel therapeutics. Professor Peter ‘t Hart and his team at the University of Münster leverage generative AI and wet-lab screening to...
Exact Sciences Launches Multi-Cancer Early Detection Liquid Biopsy Test
Exact Sciences introduced Cancerguard, a liquid biopsy test capable of detecting over 50 cancer types and subtypes through circulating tumor DNA and protein alterations. Launched at an...
Biopharma Gene Therapy Trial Paused After Patient Death
Capsida Biotherapeutics has halted its phase I/II clinical trial for gene therapy CAP-002 targeting STXBP1 encephalopathy after the death of the first patient enrolled. The pause aims to...
LB Pharmaceuticals Raises $285 Million in Biotech IPO
LB Pharmaceuticals successfully completed a $285 million initial public offering, marking the largest biotech IPO in months. The company will use the proceeds to advance its schizophrenia and...
Breakthrough Phase II Alzheimer’s Data for REM-127
Remynd NV reported positive Phase IIa results for its investigational Alzheimer's drug REM-127, demonstrating improvements in cognition and reduced tau protein pathology by targeting calcium...
Partnership to Integrate Multi-Omics and AI-Powered Lab Informatics
Sapio Sciences and Ultima Genomics have formed a strategic partnership to seamlessly combine Sapio’s AI-powered lab informatics platform with Ultima’s high-throughput, cost-effective sequencing...
Exact Sciences Launches Multi-Cancer Early Detection Test
Exact Sciences has launched Cancerguard, a multi-cancer early detection blood test capable of identifying over 50 cancer types with up to 68 percent sensitivity in the deadliest cancers. The test...
Merck and AstraZeneca Withdraw Large UK Investments Amid Industry Concerns
Merck has announced the closure of its London R&D lab, citing concerns over the UK’s life sciences policies, following similar moves by AstraZeneca and Eli Lilly. AstraZeneca paused a $271 million...
AI-Designed Peptides Revolutionize Drug Development
Researchers employing artificial intelligence have achieved unprecedented success designing novel peptides with potential therapeutic applications, transforming traditional drug discovery...
FDA Guidance Encourages Development of Non-Opioid Pain Therapies
The FDA released draft guidelines to support pharmaceutical companies in developing non-opioid medications for chronic pain management, promoting broader indications and clinical trial strategies...
Discovery of New Antibiotics from Soil Microbiomes via Long-Read Sequencing
Utilizing terabase-scale long-read sequencing, researchers have accessed previously uncultured soil bacterial genomes to uncover hundreds of new microbial species and identify novel bioactive...
Merck Pulls Out of UK Research: Impact on Life Sciences Investment
Merck has announced the termination of plans for its $1.3 billion London lab and is ceasing discovery research activities in the UK. This decision mirrors growing industry concerns over the UK...